Skip to contentC
Cumberland Pharmaceuticals Inc
C
CPIXCumberland Pharmaceuticals Inc Q4 2017 · 10-K
Revenue$11.65M$11.65M+28.3% vs Q4 2016 Net Income-$800.55K-$800.55KN/M vs Q4 2016 EPS Diluted-$0.05-$0.05N/M vs Q4 2016 Operating Income-$903,326N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Cumberland Pharmaceuticals Inc · CIK 1087294 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$562,623N/M Margins · derivedOperating margin-7.8%+2.8 pt vs Q4 2016
Net margin-6.9%+1.4 pt vs Q4 2016
ended Dec 31, 2017 · filed Mar 9, 2018 · 68 d after period end